Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Patent metadata

Field	Value
Publication number	US-11077053-B2
Application number	US-202016950574-A
Country	US
Kind code	B2
Filing date	Nov 17, 2020
Priority date	Aug 21, 2018
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

Methods of using the alpha-2-adrenergic receptor agonist of Formula I:

for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.

First claim

What is claimed is:

1. A method of treating an ocular condition in an individual in need of such treatment, the method comprising administering to the individual a therapeutically effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof; wherein the ocular condition is selected from the group consisting of presbyopia, visual glare, visual starbursts, visual halos, and night myopia; wherein the therapeutically effective amount of the compound of Formula I or pharmaceutically acceptable salt thereof is administered topically to one or both eyes of the individual as a pharmaceutically acceptable composition comprising the therapeutically effective amount of the compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient; and wherein the pharmaceutically acceptable composition comprises the compound of Formula I in an amount of from 0.01% (w/v) to 0.3% (w/v).

2. The method of claim 1 , wherein the ocular condition is presbyopia.

3. The method of claim 1 , wherein the ocular condition is visual glare.

4. The method of claim 1 , wherein the ocular condition is visual starbursts.

5. The method of claim 1 , wherein the ocular condition is visual halos.

6. The method of claim 1 , wherein the ocular condition is night myopia.

7. The method of claim 1 , wherein the pharmaceutically acceptable composition comprises the compound of Formula I in an amount of 0.01% (w/v).

8. The method of claim 1 , wherein the pharmaceutically acceptable composition comprises the compound of Formula I in an amount of 0.03% (w/v).

9. The method of claim 1 , wherein the pharmaceutically acceptable composition comprises the compound of Formula I in an amount of 0.1% (w/v).

10. The method of claim 1 , wherein the pharmaceutically acceptable composition comprises the compound of Formula I in an amount of 0.3% (w/v).

11. The method of claim 1 , wherein the method comprises administering a pharmaceutically acceptable salt of compound 1 and wherein the pharmaceutically acceptable salt is a hydrochloride salt.

Assignees

• Allergan Inc

Inventors

• Dibas Mohammed
• Gil Daniel W
• Chen Wayne
• Alcantara Miguel

Classifications

• A61K9/0048 Primary

  Eye, e.g. artificial tears · CPC title

• A61P27/02 Primary

  Ophthalmic agents · CPC title

• A61K31/4178

  not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin · CPC title

• A61P27/10

  for accommodation disorders, e.g. myopia · CPC title

• A61K9/0051

  Ocular inserts or implants · CPC title